X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-launches-direct-consumer-campaign
https://endpts.com/another-pharma-adds-direct-telehealth-with-phathoms-first-campaign-for-acid-blocker-voquezna/
https://www.globenewswire.com//news-release/2024/02/13/2828184/0/en/Phathom-Pharmaceuticals-Announces-VOQUEZNA-vonoprazan-Tablets-for-Erosive-GERD-and-Associated-Heartburn-Added-to-Express-Scripts-National-Formularies-for-Commercial-Patients.html
https://www.globenewswire.com/news-release/2023/12/06/2791702/0/en/Phathom-Pharmaceuticals-Announces-FDA-Acceptance-for-Filing-of-VOQUEZNA-vonoprazan-Tablets-New-Drug-Application-for-the-Treatment-of-Heartburn-Associated-with-Non-Erosive-GERD.html
https://www.globenewswire.com//news-release/2023/11/28/2786903/0/en/Phathom-Pharmaceuticals-Announces-Commercial-Availability-of-VOQUEZNA-vonoprazan-Tablets-a-Powerful-First-In-Class-PCAB-for-the-Treatment-of-Erosive-GERD-and-Relief-of-Associated-H.html
https://www.globenewswire.com/news-release/2023/11/01/2771786/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-vonoprazan-Tablets-for-the-Treatment-of-Erosive-GERD-and-Relief-of-Heartburn-Associated-with-Erosive-GERD-in-Adults.html
https://www.globenewswire.com//news-release/2023/10/30/2769171/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-Reformulated-Vonoprazan-Tablets-for-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amo.html
https://www.fiercepharma.com/pharma/after-reformulation-phathom-says-it-has-voquezna-back-track-approval
https://www.biospace.com/article/phathom-faces-another-delay-with-h-pylori-esophagitis-drugs-/
https://finance.yahoo.com/news/phathom-pharma-shares-fall-formal-135308207.html
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.globenewswire.com//news-release/2023/01/03/2582483/0/en/Phathom-Pharmaceuticals-Provides-Update-on-New-Drug-Application-Review-of-Vonoprazan-for-Erosive-Esophagitis.html
https://www.globenewswire.com/news-release/2022/10/24/2539893/0/en/Phathom-Pharmaceuticals-Completes-Patient-Enrollment-in-Phase-3-PHALCON-NERD-301-Daily-Dosing-Trial-of-Vonoprazan-in-Non-Erosive-Gastroesophageal-Reflux-Disease-NERD.html
https://central-south-america.evonik.com/en/evonik-and-phathom-pharmaceuticals-partner-to-produce-novel-acid-blocker-vonoprazan-179262.html
https://www.globenewswire.com/news-release/2022/10/18/2536346/0/en/Phathom-Pharmaceuticals-to-Present-Latest-Data-on-Vonoprazan-at-American-College-of-Gastroenterology-ACG-2022-Annual-Scientific-Meeting.html
https://www.wfmz.com/news/pr_newswire/pr_newswire_health/catalent-supports-u-s-launch-of-phathom-pharmaceuticals-new-products-following-regulatory-approval/article_64ab06a9-ff7e-511a-8755-88695b93ea76.html
https://www.globenewswire.com/news-release/2022/05/24/2449654/0/en/Phathom-Pharmaceuticals-Presents-Data-on-Novel-Potassium-Competitive-Acid-Blocker-PCAB-Vonoprazan-from-a-Range-of-Studies-at-Digestive-Disease-Week-DDW-2022.html
https://seekingalpha.com/news/3832522-phathom-pharma-wins-fda-approval-for-antibacterial-tablets
https://www.globenewswire.com/news-release/2022/03/14/2402533/0/en/Phathom-Pharmaceuticals-Submits-Vonoprazan-NDA-to-FDA-for-the-Treatment-of-Erosive-Esophagitis.html
https://www.globenewswire.com/news-release/2022/02/09/2382246/0/en/Phathom-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Trial-Evaluating-Vonoprazan-for-Non-Erosive-Gastroesophageal-Reflux-Disease-NERD.html
https://www.globenewswire.com/news-release/2021/10/21/2318298/0/en/Phathom-Pharmaceuticals-to-Present-New-Data-at-ACG-2021-Annual-Scientific-Meeting.html
https://endpts.com/phathoms-old-takeda-drug-bests-prevacid-in-a-phiii-gi-trial-next-stop-the-fda/
https://www.globenewswire.com/news-release/2021/09/08/2293340/0/en/Phathom-Pharmaceuticals-Submits-Two-NDAs-to-U-S-FDA-for-Vonoprazan-based-Treatment-Regimens-for-the-Treatment-of-H-pylori-Infection.html
https://www.globenewswire.com/news-release/2019/12/02/1954817/0/en/INmune-Bio-Inc-Announces-First-Alzheimer-s-Disease-Patient-Dosed-in-XPro1595-Study.html
https://endpts.com/takeda-frazier-create-phathom-pharmaceuticals-to-spur-ex-japan-development-of-gi-drug-vonoprazan/
Market Place
Share 
